Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus docetaxel versus placebo plus docetaxel in first-line metastatic castration-resistant prostate cancer
2013-000809-23Phase 3Recruiting
- Sponsor
- AB Science
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Masitinib plus docetaxel with Placebo plus docetaxel (2 arms). Primary endpoint: Overall survival. Started Mar 2014; status: recruiting.
02
Drugs
masitinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-000809-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000809-23.